Surrozen, Inc. Form 8-K Summary
Business Context and Reporting Period
Surrozen, Inc. filed a Form 8-K on May 8, 2024, under Item 2.02 to announce financial results for the quarter ended March 31, 2024. The filing references a related press release as Exhibit 99.1, but the press release content is not included in the provided filing text.
Surrozen is incorporated in Delaware and trades on the Nasdaq Capital Market under the symbols SRZN for common stock and SRZNW for redeemable warrants. The company is designated as an emerging growth company.
Financial Metrics
- The provided filing text does not provide clear values for revenue, net income or loss, operating expenses, cash flow, cash and equivalents, debt, liquidity, margins, or other quarterly financial metrics.
- The filing does not include comparative figures for the prior-year or prior-quarter period.
Material Changes Versus the Prior Comparable Period
The filing text does not provide sufficient financial or operating data to identify material changes versus the prior comparable period.
Guidance, Outlook, Risks, and Unusual Items
- No guidance, outlook, management commentary, contingencies, or unusual items are included in the provided text.
- The filing states that the Item 2.02 information, including the referenced exhibit, is furnished rather than filed for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other Securities Act filings.
Key Facts to Verify
- Review Exhibit 99.1 for the quarter’s reported revenue, net loss, operating expenses, cash position, cash burn, and any balance-sheet information.
- Verify management’s statements regarding clinical programs, pipeline progress, financing needs, and expected cash runway.
- Check for any guidance, material subsequent events, risk updates, or non-GAAP financial measures included in the omitted press release.
- Confirm the terms and status of the SRZNW redeemable warrants and any potential dilution.